NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced plans to change the ratio of its American Depository Shares (“ADSs”) to its ordinary shares from one (1) ADS, representing twenty-five ...

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company") announced plans to change the ratio of its American Depository Shares ("ADSs") to its ...

Research reveals why EGFR-targeted cancer therapies often face resistance, leading to ongoing studies on combination treatments.

A study led by UCLA has discovered that JAK inhibitors could potentially prevent or reverse immune-related diabetes triggered ...